 Coherus BioSciences Incs NASDAQ: CHRS Q4 net revenue was 73.4 million for Q4 FY21 compared to 110.4 million for the same period in 2020, missing estimates of 85.81 million. The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts. 